BioMedNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Announces Collaboration Agreement with RCFFN, University of Manitoba

March 11, 2022 13:27:48

AREV Life Sciences (CSE: AREV) (OTC: AREVF) has announced its engagement of the University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals (“RCFFN”) to complete the design and produce the prototypes of its Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs “SUSTAINN,” AREV’s next-generation Ready to Use Therapeutic Food (“RUTF”). According to the announcement, AREV, through its U.S. subsidiary in Rochester, New York, is developing the aflatoxin-free RUTF for the treatment of SAM leading to inanition. AREV’s SUSATAINN is being developed in collaboration with representatives from several academic research institutions, including the Institute for Human Virology (“IHV”), The Linus Pauling Institute (“LPI”) at Oregon State University (“OSU”) and the RCFFN at the University of Manitoba. “AREV’s development of SUSATAINN is now being enhanced by this collaboration with the Richardson Centre for Functional Foods and Nutraceuticals at the University of Manitoba,” said Dr. Roscoe Moore, chairman of the scientific advisory board for AREV Life Sciences, and board member of Global Virus Network. “Our product development and research from Linus Pauling Institute has provided the initial data to be applied with the scientists at the Richardson Centre for Functional Foods and Nutraceuticals in order to accelerate the introduction of SUSTAINN into public health commodity procurement program utilization to combat global famine and serious and acute malnutrition during the intersection of COVID-19 and other pandemic infections that are driving a global decline of life expectancy and childhood mortality.”

To view the full press release, visit https://ibn.fm/5NZZF

About AREV Life Sciences Global Corp.

AREV Life Sciences is a fully integrated, publicly traded, early stage life science enterprise dedicated to delivering therapeutic interventions to public health through extraction of unique compounds, discovery, innovation and successful collaborations. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations in human nutrition. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (“BIO”). For more information, visit www.AREVLifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to AREVF are available in the company’s newsroom at https://ibn.fm/AREVF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork